EE440 Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination in Adults Aged 50-59 Years With Cardiopulmonary Diseases in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.735
https://www.valueinhealthjournal.com/article/S1098-3015(24)00850-7/fulltext
Title :
EE440 Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination in Adults Aged 50-59 Years With Cardiopulmonary Diseases in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00850-7&doi=10.1016/j.jval.2024.03.735
First page :
Section Title :
Open access? :
No
Section Order :
10202